High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Schehr, Jennifer L ^a   Schultz, Zachery D ^a   Warrick, Jay W ^b   Guckenberger, David J ^b   Pezzi, Hannah M ^b   Sperger, Jamie M ^a   Heninger, Erika ^a   Saeed, Anwaar ^a,c   Leal, Ticiana ^a,c   Mattox, Kara ^a   Traynor, Anne M ^a,c   Campbell, Toby C ^a,c   Berry, Scott M ^b   Beebe, David J ^b   Lang, Joshua M ^a,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b University of Wisconsin Madison   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; CELL ANTIBODY; CYTOKERATIN; EPITHELIAL CELL ADHESION MOLECULE; MUCIN 1; PROGRAMMED DEATH 1 LIGAND 1; VIMENTIN; TUMOR MARKER;

ARTICLE; BLOOD BUFFY COAT; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SPECIFICITY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MEASUREMENT ACCURACY; NON SMALL CELL LUNG CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOPHENOTYPING; LUNG NEOPLASMS; METABOLISM; METASTASIS; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS; TUMOR EMBOLISM;

ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOPHENOTYPING; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84979998430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159397     Document Type: Article

References (43)

1. Casavant BP, Strotman LN, Tokar JJ, Thiede SM, Traynor AM, Ferguson JS, et al. Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform. Lab Chip. 2014; 14(1):99-105. Epub 2013/10/26. doi: 10.1039/c3lc50912e PMID: 24158597; PubMed Central PMCID: PMCPMC3897162.
2. Casavant BP, Guckenberger DJ, Beebe DJ, Berry SM. Efficient sample preparation from complex biological samples using a sliding lid for immobilized droplet extractions. Anal Chem. 2014; 86(13):6355-62. doi: 10.1021/ac500574t PMID: 24927449; PubMed Central PMCID: PMCPMC4079323.
3. Sperger JM, Strotman LN, Welsh A, Casavant BP, Chalmers Z, Horn S, et al. Integrated analysis of multiple biomarkers from circulating tumor cells enabled by exclusion-based analyte isolation. Clin Cancer Res. 2016.
4. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(23):7053-8. doi: 10.1158/1078-0432.CCR-07-1506 PMID: 18056182.
5. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005; 23(7):1420-30. doi: 10.1200/JCO.2005.08.140 PMID: 15735118.
6. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011; 29 (12):1556-63. doi: 10.1200/JCO.2010.28.7045 PMID: 21422424.
7. Reis LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L. SEER Cancer Statistics Review, 1975-2002 2005 [cited 2016 23 Feb]. Available from: http://seer.cancer.gov/archive/csr/1975-2002/.
8. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373 (2):123-35. Epub 2015/06/02. doi: 10.1056/NEJMoa1504627 PMID: 26028407; PubMed Central PMCID: PMCPMC4681400.
9. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. Epub 2015/09/29. doi: 10.1056/NEJMoa1507643 PMID: 26412456.
10. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015. Epub 2015/12/30. doi: 10.1016/s0140-6736(15)01281-7 PMID: 26712084.
11. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. doi: 10.1158/1078-0432.CCR-04-0378 PMID: 15501967.
12. Gorczyca W, Sun ZY, Cronin W, Li X, Mau S, Tugulea S. Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Methods Cell Biol. 2011; 103:221-66. doi: 10.1016/B978-0-12-385493-3.00010-3 PMID: 21722806.
13. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001; 166(1):678-89. PMID: 11123353.
14. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia. 1997; 11(11):1878-86. PMID: 9369421.
15. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001; 61(12):4756-60. PMID: 11406548.
16. Streicher J, Fabian B, Herkner K, Pointner H, Bayer PM. Anticytokeratins are a potential source of false-positive indirect immunofluorescence assays for C-ANCA. J Clin Lab Anal. 1998; 12(1):54-9.PMID: 9484670.
17. Moisan E, Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol. 2006; 79(3):489-98. doi: 10.1189/jlb.0405190 PMID: 16365157.
18. Pericle F, Sconocchia G, Titus JA, Segal DM. CD44 is a cytotoxic triggering molecule on human polymorphonuclear cells. J Immunol. 1996; 157(10):4657-63. PMID: 8906846.
19. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012; 7(2):306-15. doi: 10.1097/JTO.0b013e31823c5c16 PMID: 22173704.
20. Wang JF, Li JB, Zhao YJ, Yi WJ, Bian JJ, Wan XJ, et al. Up-regulation of programmed cell death 1 ligand 1 on neutrophils may be involved in sepsis-induced immunosuppression: an animal study and a prospective case-control study. Anesthesiology. 2015; 122(4):852-63. doi: 10.1097/ALN.0000000000000525 PMID: 25437496.
21. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003; 170(3):1257-66. PMID: 12538684.
22. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014; 9(3):694-710. doi: 10.1038/nprot. 2014.044 PMID: 24577360; PubMed Central PMCID: PMCPMC4179254.
23. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013; 5(179):179ra47. doi: 10.1126/scitranslmed.3005616 PMID: 23552373; PubMed Central PMCID: PMCPMC3760275.
24. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007; 13(2 Pt 2):721s-6s. doi: 10.1158/1078-0432.CCR-06-2197 PMID: 17255300.
25. Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res. 2004; 28(1):43-8. PMID: 14630079.
26. Warrick JW, Timm A, Swick A, Yin J. Tools for Single-Cell Kinetic Analysis of Virus-Host Interactions. PLoS One. 2016; 11(1):e0145081. Epub 2016/01/12. doi: 10.1371/journal.pone.0145081 PMID: 26752057; PubMed Central PMCID: PMCPMC4713429.
27. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014; 74(6):1645-50. Epub 2014/01/23. doi: 10.1158/0008-5472.can-13-1739 PMID: 24448245; PubMed Central PMCID: PMCPMC3959622.
28. Warrick JW. JEX CTC Plugins [cited 2016 23 Feb]. Available from: https://github.com/jaywarrick/JEX-CTCPlugins.
29. Verschoor CP, Lelic A, Bramson JL, Bowdish DM. An Introduction to Automated Flow Cytometry Gating Tools and Their Implementation. Front Immunol. 2015; 6:380. doi: 10.3389/fimmu.2015.00380 PMID: 26284066; PubMed Central PMCID: PMCPMC4515551.
30. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004; 122(1):61-9. Epub 2004/07/27. doi: 10.1309/9r66-73qe-c06d-86y4 PMID: 15272531.
31. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015; 349(6254):1351-6. doi: 10.1126/science.aab0917 PMID: 26383955.
32. Joosse SA, Hannemann J, Spotter J, Bauche A, Andreas A, Muller V, et al. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res. 2012; 18(4):993-1003. Epub 2012/01/10. doi: 10.1158/1078-0432.ccr-11-2100PMID: 22228641.
33. de Wit S, van Dalum G, Lenferink AT, Tibbe AG, Hiltermann TJ, Groen HJ, et al. The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci Rep. 2015; 5:12270. Epub 2015/07/18. doi: 10. 1038/srep12270 PMID: 26184843; PubMed Central PMCID: PMCPMC4505332.
34. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, et al. Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol. 2011; 2011:252361. Epub 2011/05/18. doi: 10.1155/2011/252361 PMID: 21577258; PubMed Central PMCID: PMCPMC3090615.
35. Schneck H, Gierke B, Uppenkamp F, Behrens B, Niederacher D, Stoecklein NH, et al. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer. PLoS One. 2015; 10(12): e0144535. Epub 2015/12/24. doi: 10.1371/journal.pone.0144535 PMID: 26695635; PubMed Central PMCID: PMCPMC4687932.
36. Dent BM, Ogle LF, O'Donnell RL, Hayes N, Malik U, Curtin NJ, et al. High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. Int J Cancer. 2016; 138(1):206-16. Epub 2015/07/17. doi: 10.1002/ijc.29680 PMID: 26178530; PubMed Central PMCID: PMCPMC4737101.
37. Alix-Panabieres C, Pantel K. Technologies for detection of circulating tumor cells: facts and vision. Lab Chip. 2014; 14(1):57-62. Epub 2013/10/23. doi: 10.1039/c3lc50644d PMID: 24145967.
38. Danila DC, Pantel K, Fleisher M, Scher HI. Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J. 2011; 17(6):438-50. Epub 2011/12/14. doi: 10.1097/PPO.0b013e31823e69ac PMID: 22157288; PubMed Central PMCID: PMCPMC3985131.
39. Casavant B, Kosoff D, Lang J. Directing Circulating Tumor Cell Technologies Into Clinical Practice. In: Fan Z, editor. Circulating Tumor Cells, Isolation and Analysis: Wiley; 2016. p. 351-64.
40. Nair KS, Zingde SM. Adhesion of neutrophils to fibronectin: role of the cd66 antigens. Cell Immunol. 2001; 208(2):96-106. Epub 2001/05/03. doi: 10.1006/cimm.2001.1772 PMID: 11333142.
41. Alon R, Bayer EA, Wilchek M. Streptavidin contains an RYD sequence which mimics the RGD receptor domain of fibronectin. Biochem Biophys Res Commun. 1990; 170(3):1236-41. Epub 1990/08/16.PMID: 2390089.
42. BioGPS-your Gene Portal System 2016. Available from: http://biogps.org/#goto=genereport&id=367.
43. Zhang J, Qiao X, Shi H, Han X, Liu W, Tian X, et al. Circulating tumor-associated neutrophils (cTAN) contribute to circulating tumor cell survival by suppressing peripheral leukocyte activation. Tumour Biol. 2016; 37(4):5397-404. Epub 2015/11/14. doi: 10.1007/s13277-015-4349-3 PMID: 26563367.